Recent News

By Category: Countermeasures

CDC Award for Ricin Kits to Radix BioSolutions

The Centers for Disease Control and Prevention has announced intentions to award a sole source order to Radix BioSolutions for Ricin Components Differentiation Assay Kits. “Ricin detection kits produced by Radix BioSolutions have been validated via testing conducted at other state … Continue reading →

April 23, 2013
| Filed under Countermeasures
Share

U.S. Navy Development of Malaria Vaccines

The Naval Medical Research Center (NMRC) earlier this month announced a requirement for a supporting consultant to assist in the development of a malaria vaccine for use by military personnel and presentation of NMRC data at international conferences and via … Continue reading →

April 23, 2013
| Filed under Countermeasures
Share

Hepatitis C drug nears approval

Posted on behalf of Beth Mole. A highly anticipated new drug for treating hepatitis C has sailed through its first phase III clinical trials, according to two papers published today in the New England Journal of Medicine. Sofosbuvir, a new antiviral developed by Gilead Sciences of Foster City, California, is one of several drugs in Read More »

April 23, 2013
| Filed under Countermeasures
Share

Improved Detection Test Developed To Identify Food Contamination, Aid Bioterrorism Defense

Sales of chicken products in China plummeted recently during an outbreak of a deadly new strain of bird flu. From bird flu to mad cow disease, numerous food scares have made global headlines in recent years. A technique developed by University of Missouri Professor of Engineering Shubhra Gangopadhyay’s group may make food contamination testing more Read More »

April 23, 2013
| Filed under Countermeasures and Public Health
Share

Phase I Clinical Trial For An H5N1 Bird Flu Vaccine Shows Positive Results

(MedicalNewsToday) IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim Read More »